We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

39 hedge funds and large institutions have $64.6M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

30% more capital invested

Capital invested by funds: $49.6M → $64.6M (+$15M)

15% more funds holding

Funds holding: 34 → 39 (+5)

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
7
Reduced
5
Closed
5
Calls
$15K
Puts
–
Net Calls
+$15K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$9.8M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.97M
3
ECU
Eisler Capital (UK)
United Kingdom
+$2.28M
4
Bank of America
Bank of America
North Carolina
+$1.39M
5
CIM
Cowen Investment Management
New York
+$732K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$3.22M
2
AA
AQR Arbitrage
Connecticut
-$833K
3
SC
Shay Capital
New York
-$663K
4
MP
Mangrove Partners
Connecticut
-$313K
5
BlackRock
BlackRock
New York
-$244K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$9.76M +$9.8M +999,999 New
BlackRock
2
BlackRock
New York
$8.79M -$244K -24,868 -3%
6CM
3
683 Capital Management
New York
$5.86M – – –
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$4.67M +$2.97M +302,988 +172%
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$4.23M – – –
ACM
6
Altium Capital Management
New York
$3.9M – – –
CH
7
CVI Holdings
Delaware
$3.46M – – –
ECU
8
Eisler Capital (UK)
United Kingdom
$2.27M +$2.28M +232,600 New
EC
9
EcoR1 Capital
California
$1.95M – – –
KCM
10
Kingdon Capital Management
New York
$1.95M – – –
FTCM
11
First Trust Capital Management
Illinois
$1.64M – – –
Bank of America
12
Bank of America
North Carolina
$1.39M +$1.39M +142,074 New
CIM
13
Cowen Investment Management
New York
$1.22M +$732K +74,726 +149%
Millennium Management
14
Millennium Management
New York
$1.14M -$1.96K -200 -0.2%
Jane Street
15
Jane Street
New York
$1.04M – – –
CC
16
Centiva Capital
New York
$1.02M – – –
ACA
17
Arena Capital Advisors
California
$976K – – –
RCM
18
Radcliffe Capital Management
Pennsylvania
$976K – – –
RCM
19
Rivernorth Capital Management
Florida
$976K – – –
SCM
20
Suvretta Capital Management
New York
$976K – – –
PC
21
Periscope Capital
Ontario, Canada
$766K – – –
CFIA
22
Cantor Fitzgerald Investment Advisors
New York
$722K +$725K +74,000 New
HIH
23
HRS Investment Holdings
New York
$722K +$725K +74,000 New
SIA
24
SkyView Investment Advisors
New Jersey
$701K +$52K +5,310 +8%
GCL
25
Glazer Capital LLC
New York
$654K +$657K +66,990 New
1
2

EUCR Hedge Fund Activity: Q4 2021 in Review

39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q4 2021, worth a combined $64.6M — up 30% from $49.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EUCR positions and 5 closed out — a net gain of 5 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $9.8M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.22M sold.

  • 39 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q4 2021, up from 34 in Q3 2021.
  • Funds reported $64.6M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q4 2021, up 30% quarter-over-quarter.
  • 10 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q4 2021 and 5 closed out, a net change of +5 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q4 2021 was Deerfield Management, an estimated $9.8M added.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q4 2021 was Sphera Funds Management, an estimated $3.22M sold.

Based on aggregated 13F filings for Q4 2021.